(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 16.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Karyopharm Therapeutics's revenue in 2025 is $137,269,000.On average, 3 Wall Street analysts forecast KPTI's revenue for 2025 to be $1,277,045,125, with the lowest KPTI revenue forecast at $1,261,150,672, and the highest KPTI revenue forecast at $1,290,112,741. On average, 3 Wall Street analysts forecast KPTI's revenue for 2026 to be $1,392,052,285, with the lowest KPTI revenue forecast at $1,344,048,090, and the highest KPTI revenue forecast at $1,449,837,682.
In 2027, KPTI is forecast to generate $2,117,872,939 in revenue, with the lowest revenue forecast at $2,117,872,939 and the highest revenue forecast at $2,117,872,939.